RE:RE:RE:The full article published yesterday It is a long and complex article, going through it what they are talking about is the fact that TH1902 has a bystander effect on a molecular level which trigger immune cell infiltration. Also TH1902 again through a cascades of molecular activities reduces anti-tumor immunity leading to increase recognition of cytotoxicity and an increase of the cell surface immunotherapy agent.
That is why the combination of the PDC and anti-PD-L1 can relativly bypass the resistance mechanism. I know it all sounds a bit complicated and quite frankly the molecular mechanism they are talking about is above my paygrade however this is to my knowledge a new discovery and another mechanism of action which was not studied before reinforcing the idea of the synergistic anti-cancer effect of TH1902 together with anti-PD-L1. The point is although very early preclinical stuff each and every one of these findings could potentially lead to a new combo treatment fighting resistant heterogonous cancers. Would they add value to the Sort1 platform’s potentials and make it more attractive to the potential partners my take absolutely yes.
palinc2000 wrote: The reason for me asking what is NEW is to try to handicap if there could be renewed interest by a large pharma to take over or share the responsibility of the Clinical trial......For me this is what needs to happen
palinc2000 wrote: Great post once again!
Are you able to break down what is actually NEW data in this study which appears to be quite extensive.....?
scarlet1967 wrote: "In conclusion, this is the first in vivo preclinical study to document that administration of TH1902 is better tolerated, based on non-significant mice body weight loss, and more effective than docetaxel at inhibiting tumor growth in an immunocompetent syngeneic “cold” tumor model. Among the salient in vivo findings complementing the TH1902-mediated increase in the infiltration of tumor parenchyma by most classes of leukocytes, was that combining TH1902 with an anti-PD-L1 CPI produced a significantly greater reduction in tumor size than did the combination of anti-PD-L1 with docetaxel. In addition, the survival study reported herein clearly demonstrated that animals treated with TH1902 had a dose-dependent increase in survival, an effect potentiated by co-administration with anti-PD-L1 in a cold tumor model. Finally, the sustained and prolonged effects of TH1902 in our preclinical in vivo studies, even off-treatment and following six cycles, reflects the preliminary Phase 1 observations of prolonged clinical benefits, even after treatment discontinuation."
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1355945/full
This is the full article discussing in details the combo effects of TH1902 and anti PD-L1. Apart from details how and why the combo effect works they are also talking about bystander effects and prolonged off-treatment effects similarly to what they saw in the part 1 and 2 of the phase1 clinical trial.